9.3 Connecticut Opioid Supply Limits (7-day / 5-day)

Why a first-fill opioid is not “whatever the blank says”

Quick Answer: CGS § 20-14o limits an adult’s first-time outpatient opioid to a 7-day supply and limits an opioid issued to a minor to a 5-day supply. The prescriber may exceed those numbers when professional medical judgment requires more for an acute condition, chronic pain, cancer-associated pain, or palliative care, and then documents the condition and that an alternative was not appropriate. Do not memorize “Connecticut never allows more than 7 days.” A 30-day first oxycodone for acute dental pain is still a corresponding-responsibility red flag for the pharmacist.

NABP Competency 2.1.1 tests uses and limits of prescriptions. Federal CSA does not impose Connecticut’s 7-day / 5-day opioid supply rules. More-restrictive Connecticut law wins. DCP’s knowledge-base article “Connecticut Laws Impacting Prescribing and Practice” (current DCP page dated April 28, 2025) is the agency’s own timeline of those overlay statutes. Read it next to § 20-14o, not instead of it.

DCP’s timeline — then the statute that actually binds the fill

DCP’s prescribing-practice page groups the opioid overlay by year:

• 2016: Opioid prescriptions for first-time outpatient use are limited to a 7-day supply. The mandate maintains the prescriber’s professional judgment to prescribe more than a 7-day supply for ongoing use when needed. Education is required for patients under 18 and their guardians on addiction, overdose, and combining opioids with alcohol, benzodiazepines, and other depressants.
• 2017: The number of days an opioid can be prescribed on a first visit is limited to five days for patients who are minors. Patients may opt out of being prescribed opioids with a voluntary non-opioid directive form. EPCS becomes the default for controlled-substance prescriptions (emergency and technology exceptions — Chapter 8).
• 2019: Patients prescribed opioids for pain for 12 weeks or more must have written documentation in the medical record covering risks, urine drug screening, why treatment might be discontinued, and alternative pain options.
• 2023: Prescribers should encourage patients to obtain an opioid antagonist (naloxone) when an opioid is prescribed.

CGS § 20-14o is the fill-desk statute those bullets describe.

Adults — subsection (b). When issuing an opioid to an adult (at least 18) for the first time for outpatient use, a practitioner authorized to prescribe an opioid shall not issue a prescription for more than a seven-day supply, as recommended in CDC’s Guideline for Prescribing Opioids for Chronic Pain. DCP’s practitioner PDF is explicit that the 7-day limit does not apply to subsequent opioid prescriptions issued to that adult for outpatient use. First fill is the trap. The second hydrocodone prescription two weeks later is not automatically a 7-day prescription — though corresponding responsibility and CPMRS still apply.

Minors — subsection (c). A practitioner shall not issue a prescription for an opioid drug to a minor for more than a five-day supply. DCP’s laws-impacting page summarizes the 2017 change as a first-visit 5-day limit. DCP’s prescribing PDF says minors shall not exceed a five-day supply at any time. The statute’s text is a 5-day ceiling on an opioid issued to a minor, not a sentence that expires after visit one. On the MPJE, prefer § 20-14o(c) plus the subsection (d) exception. Do not invent a loophole that a minor’s second visit automatically unlocks 30 days.

The professional-judgment exception — do not say “never more than 7 days”

CGS § 20-14o(d) is the sentence commercial outlines skip. Notwithstanding (b) and (c), if in the practitioner’s professional medical judgment more than a 7-day supply is required to treat an adult’s acute medical condition, or more than a 5-day supply is required to treat a minor’s acute medical condition, or more is necessary for chronic pain, pain associated with a cancer diagnosis, or palliative care, the practitioner may issue a prescription for the quantity needed. The condition triggering the larger supply shall be documented in the patient’s medical record, and the practitioner shall indicate that an alternative to the opioid was not appropriate to address that condition.

That is not a blank check, and it is not a prohibition. Teach it as a documented exception:

Subsection (e) removes medications designed for the treatment of abuse of or dependence on an opioid drug, including opioid agonists and opioid antagonists, from (b), (c), and (d). Buprenorphine for OUD is not a “first-time outpatient pain opioid” for the 7-day rule. Naloxone as an antagonist is not either.

Education, opt-out, 12 weeks, naloxone — the rest of the overlay

CGS § 20-14o(f) requires the practitioner, when issuing an opioid to an adult or minor, to discuss the risks of addiction and overdose and the dangers of taking opioids with alcohol, benzodiazepines, and other CNS depressants, and the reasons the prescription is necessary — and, if applicable, with the custodial parent, guardian, or other person having legal custody of a minor if that person is present at issuance. DCP’s 2016 bullet on education for patients under 18 is this discussion duty.

CGS § 20-14r is the voluntary non-opioid directive. A patient may file a form asking not to be issued an opioid. Pharmacists will see this as a prescriber-side file more often than as a pharmacy form, but a patient who states they have a directive is not a candidate for an opportunistic opioid fill.

CGS § 20-14s (2019; later technical updates) requires a practitioner who prescribes an opioid for the treatment of pain for a duration greater than twelve weeks to establish a treatment agreement with the patient or discuss a care plan for chronic opioid use. The agreement or plan includes, at a minimum, treatment goals, risks of using opioids, urine drug screens, expectations (including situations requiring discontinuation), and, to the extent possible, nonopioid options (manipulation, chiropractic, spinal cord stimulation, massage, acupuncture, physical therapy, and other modalities). A record of the agreement or plan goes in the medical record. DCP’s 2019 bullet is this statute.

2023 (PA 23-97, codified in § 20-14o): when issuing an opioid, the practitioner shall encourage the patient to obtain an opioid antagonist, and shall encourage a present parent or guardian of a minor to do the same. DCP’s page says prescribers should encourage naloxone when an opioid is prescribed. That is encouragement, not a statute that every oxycodone fill is void unless naloxone is co-dispensed. Chapter 10 covers pharmacist naloxone prescribing; this chapter only needs the prescriber-encouragement overlay that a pharmacist should expect to see in the opioid counseling conversation.

Corresponding responsibility at the Connecticut counter

21 CFR 1306.04 and Connecticut practice still impose corresponding responsibility for a controlled-substance prescription issued for a legitimate medical purpose in the usual course of professional practice. § 20-14o is a prescriber day’s-supply statute. It does not convert the pharmacist into a clerk who must fill any signed 30-day opioid. Chapter 12 develops corresponding responsibility in full; the opioid-limit application is here.

A 30-day first-fill oxycodone for acute dental pain is the prototype red flag, even if the dentist wrote it. The adult first-outpatient cap is 7 days unless subsection (d) is in play. Acute dental pain after a routine extraction is not cancer pain, is not palliative care, and is not an obvious “chronic pain” diagnosis. A dentist who believes an acute condition truly needs more than 7 days must document that condition and that an alternative was not appropriate. A pharmacy that never asks, never checks CPMRS, and never calls, then dispenses 120 tablets of oxycodone 5 mg to a first-time dental patient, is not saved by “the prescription was valid on its face.”

Practical pharmacist moves on a facially excessive first opioid:

• Confirm whether this is truly a first outpatient opioid for this adult (profile, CPMRS).
• Compare day’s supply to 7 (adult first) or 5 (minor).
• If the quantity exceeds the default, look for a chronic / cancer / palliative / documented acute rationale. Absence of any such story is a reason to contact the prescriber or decline.
• A documented (d) exception for ongoing cancer pain is the opposite fact pattern: do not reject a 30-day morphine solely because “Connecticut is 7 days.” That slogan is false.
• Offer or encourage naloxone in the same encounter; that matches the 2023 overlay even though the pharmacist’s own naloxone authority lives in Chapter 10.

Realistic Connecticut scenarios

A 22-year-old in Stamford presents a first outpatient prescription for oxycodone 5 mg, #120, SIG 1 Q6H PRN, 30-day supply, written after a wisdom-tooth extraction, with no chart note arriving and no chronic-pain diagnosis in CPMRS. § 20-14o(b)’s default is 7 days. Acute dental pain is exactly the indication the 2016 7-day rule was aimed at. Fill-as-written is a corresponding-responsibility failure. Call the dentist, document, and if the dentist cannot support a (d) exception, do not dispense the 30-day quantity.

A 16-year-old in New Britain presents a 5-day hydrocodone prescription after an orthopedic procedure, and a parent is at the counter. The day’s supply matches § 20-14o(c). The counseling conversation still includes addiction, overdose, alcohol/benzodiazepine risk, and encouragement to obtain naloxone for the minor and the parent.

A 68-year-old on months of morphine for metastatic cancer presents a 30-day refill-equivalent new CII. Subsection (b)’s first-fill 7-day cap does not apply to this subsequent / ongoing use, and subsection (d) independently authorizes the quantity needed for cancer-associated pain. § 20-14s expects a treatment agreement or care plan in the medical record once pain opioid therapy exceeds 12 weeks. The pharmacist is not the author of that agreement, but a profile with no pain-contract story, escalating doses, and early fills can still be a corresponding-responsibility problem — for a different reason than the 7-day rule.

Official anchors

• CGS § 20-14o — 7-day adult first outpatient opioid; 5-day minor; documented professional-judgment exception; OUD-medication carve-out; risk discussion; 2023 naloxone encouragement.
• CGS § 20-14r — voluntary non-opioid directive.
• CGS § 20-14s — treatment agreement or care plan when pain opioid therapy exceeds 12 weeks.
• DCP, Connecticut Laws Impacting Prescribing and Practice — 2016 7-day first outpatient opioid; 2017 minor 5-day / non-opioid directive; 2019 12-week documentation; 2023 naloxone encouragement.